Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abetimus sodium for prevention of renal flares in systemic lupus erythematosus with prior renal disease
2008-004852-62Phase 3Terminated
- Sponsor
- Azienda Ospedaliera Universitaria Luigi Vanvitelli
- Start
- Jan 2009
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in systemic lupus erythematosus (SLE) comparing Riquent with Placebo (2 arms). Primary endpoints: Time to documented renal flare and Incidence of documented renal flares. Started Jan 2009; status: terminated.
02
Drugs
abetimus sodium
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on 2008-004852-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004852-62.